Navigation Links
Gene therapy prevents the onset of diabetic symptoms in mice

Acid rain, the environmental consequence of burning fossil fuels, running factories and driving cars, has altered soils and reduced the number of sugar maple trees growing in the Northeast, according to a new study led by Cornell University researchers.

The sugar maple is the most economically valuable tree species in the eastern United States because of its high-priced lumber, syrup and tourist-attracting fall colors.

The study, whose lead author, Stephanie Juice '04, was an undergraduate when the research was conducted, suggests that because acid rain makes the soil more acidic, unfavorable conditions are created for sugar maples. In acidic soils, sugar maples produce fewer seedlings that survive and mature, and more adult trees die, the researchers found. They drew these conclusions after adding nutrients to soil in a test plot and reproducing the favorable soil conditions that existed prior to 20th century industrial pollution. The result: Sugar maples on the plot rebounded dramatically.

The study provides "the most conclusive evidence to date" that the decline of sugar maples is linked to the effects of acid rain produced by human activity, said Timothy Fahey, professor of forest ecology at Cornell and co-author of the study, which is published in the May issue of Ecology. Juice wrote the main part of the paper as part of her senior thesis.

"The research addresses how a long-term, human-caused change in the environment is affecting sugar maples, which are valuable both ecologically and economically as one of the dominant species in our region," said Juice, who now works for the Institute of Ecosystem Studies in Milbrook, N.Y., as a project assistant and is applying to the Peace Corps for next year.

The research was conducted at Hubbard Brook Experimental Forest (HBEF), a 3,160-hectare reserve near North Woodstock, N.H., where scientists have measured soil composition for the past 50 years. The scientists added nutrient
'"/>

Source:University of Pittsburgh Medical Center


Page: 1 2 3

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene therapy prevents the onset diabetic symptoms mice

(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:7/2/2015)... Sweden , July 2, 2015 ... sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... 2015. The sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of approximately ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... Fool me once, shame on you. Fool me twice, shame ... Carilion Research Institute have found that suspicion resides in two ... central role in processing fear and emotional memories, and the ... recognition of scenes. "We wondered how individuals assess ...
... 2012. Wiley-Blackwell, the scientific, technical, medical and scholarly publishing business ... of Food Science & Nutrition as part of ... authors with a new platform for the rapid dissemination of ... the Society of Chemical Industry, the Institute of Food Science ...
... an industry-supported program led by Stanford University and ... first research grants aimed at making utility-scale solar ... A total of $7.5 million will be ... institutions Stanford, UC-Berkeley, Lawrence Berkeley National Laboratory (LBNL), ...
Cached Biology News:Suspicion resides in 2 regions of the brain 2Suspicion resides in 2 regions of the brain 3Wiley-Blackwell launches new open-access journal: Food Science & Nutrition 2Bay Area PV Consortium announces $7.5 million in grants to lower the cost of large-scale solar 2Bay Area PV Consortium announces $7.5 million in grants to lower the cost of large-scale solar 3Bay Area PV Consortium announces $7.5 million in grants to lower the cost of large-scale solar 4
(Date:7/30/2015)... 30, 2015 According to a ... Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, ... Clinical Trial), by End Users - Global Forecast to ... to reach USD 2,107.99 million by 2020 from USD ... Browse more than 75 ...
(Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
(Date:7/30/2015)... 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor management ... safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... 2015 HIGHLIGHTS:Q2 2015 Results (all ... , Reported sales were $697 million compared to $701 ... organically by 8%, and changes in foreign currency exchange ... by 1%. , By business unit, organic sales ... 11% in SAFC Commercial. , Reported diluted EPS ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... N30 Pharma (N30), a,biopharmaceutical company focused on ... nitric oxide bioavailability,announced today that it has completed ... N30 will use proceeds from this financing to ... its discovery and preclinical,research in the area of ...
... Flavor Ingredient Achieves ... Collaboration Milestone, SAN DIEGO, CA - ... company focused on using proprietary,technologies to discover and develop novel flavor ... it has,received a payment from The Coca-Cola Company (NYSE: KO ...
... Live On Company,s Website -, TUSTIN, Calif., Oct. ... clinical stage biopharmaceutical,company developing monoclonal antibodies for the treatment ... management will,present at the BIO Investor Forum 2008 on ... EDT). The conference will be held at the Palace ...
Cached Biology Technology:N30 Pharma Announces Financing, Expansion of Board 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 3Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008 2
... clone E978 GenBank ... Immunogen : NY-ESO-1 ... mouse ascites with 0.05% ... routinely evaluated by immunoblot ...
R26.4C...
Form: Ready to use Applications: ELISA...
... tables offer precision motorized rotation and angular ... Parkers linear positioners and its low profile ... , Preloaded, precision worm gear , ... preloaded angular contact support bearing , Runout/Concentricity ...
Biology Products: